Drug intelligence / Profile preview

Nasaries

Development stage: Unknown
Lead developer: CEOLIA Pharma
Administration: Intranasal

Overview

Nasaries is a nasal cavity mucosal protectant developed and marketed by CEOLIA Pharma. Classified as a medical device, it is designed to provide a protective covering for the nasal mucosa, acting as a physical barrier. It was launched in Japan in 2022 for use in ear, nose, and throat (ENT) applications where mucosal protection is indicated, such as protecting or covering the nasal mucosa during treatment or irritation.

Brand names: Nasaries
Other names: nasal cavity mucosal protectant

Beyond the preview

Go deeper on Nasaries.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nasaries.

Explore the full profile